Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13895
UPID:
BYST_HUMAN
Alternative names:
-
Alternative UPACC:
Q13895; Q6P5W4; Q86W44; Q96IP8
Background:
Bystin plays a crucial role in the processing of 20S pre-rRNA precursor and the biogenesis of 40S ribosomal subunits. It is also essential for trophinin-dependent regulation of cell adhesion during the implantation of human embryos. This protein's involvement in fundamental cellular processes highlights its importance in the maintenance and regulation of cellular functions.
Therapeutic significance:
Understanding the role of Bystin could open doors to potential therapeutic strategies. Its critical function in ribosomal biogenesis and embryo implantation suggests that targeting Bystin could offer new avenues for treating diseases related to cell growth and reproduction.